Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) was the recipient of a significant growth in short interest in July. As of July 15th, there was short interest totaling 9,938 shares, a growth of 210.4% from the June 30th total of 3,202 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 6,876 shares, the days-to-cover ratio is presently 1.4 days.

Pharming Group Trading Down 0.1%

Shares of PHAR stock opened at $12.61 on Monday. Pharming Group has a fifty-two week low of $9.54 and a fifty-two week high of $21.34. The stock has a market cap of $892.18 million, a P/E ratio of 78.79 and a beta of -0.04. The business has a fifty day simple moving average of $13.12 and a 200-day simple moving average of $15.39. The company has a quick ratio of 2.06, a current ratio of 2.63 and a debt-to-equity ratio of 0.35.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.12). Pharming Group had a return on equity of 4.64% and a net margin of 3.30%.The firm had revenue of $72.45 million for the quarter, compared to analyst estimates of $92.06 million. On average, analysts forecast that Pharming Group will post 0.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

PHAR has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings cut shares of Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Zacks Research upgraded shares of Pharming Group from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Finally, Canaccord Genuity Group began coverage on shares of Pharming Group in a report on Friday, April 10th. They set a “buy” rating and a $37.00 price objective on the stock. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $38.33.

Hedge Funds Weigh In On Pharming Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC purchased a new stake in shares of Pharming Group in the second quarter valued at about $32,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Pharming Group in the fourth quarter valued at approximately $224,000. Millennium Management LLC purchased a new position in shares of Pharming Group during the 4th quarter worth approximately $360,000. Finally, NewEdge Advisors LLC increased its stake in shares of Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after purchasing an additional 28,615 shares in the last quarter. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.